Last reviewed · How we verify

Neostigmine Injection

Taipei Veterans General Hospital, Taiwan · FDA-approved active Small molecule

Neostigmine inhibits acetylcholinesterase, allowing acetylcholine to accumulate at neuromuscular junctions and enhance muscle contraction.

Neostigmine inhibits acetylcholinesterase, allowing acetylcholine to accumulate at neuromuscular junctions and enhance muscle contraction. Used for Myasthenia gravis, Reversal of neuromuscular blockade, Postoperative urinary retention.

At a glance

Generic nameNeostigmine Injection
Also known asglycopyrrolate
SponsorTaipei Veterans General Hospital, Taiwan
Drug classCholinesterase inhibitor
TargetAcetylcholinesterase
ModalitySmall molecule
Therapeutic areaNeurology
PhaseFDA-approved

Mechanism of action

Neostigmine is a reversible cholinesterase inhibitor that prevents the breakdown of acetylcholine by blocking the enzyme acetylcholinesterase. This leads to increased acetylcholine concentration at the neuromuscular junction, enhancing parasympathomimetic effects and improving muscle strength in conditions characterized by neuromuscular dysfunction.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: